These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Immunosuppressive drugs in the treatment of diseases belonging to the psoriasis group]. Ruszczak Z Pol Tyg Lek; 1974 Jun; 29(24):1051-3. PubMed ID: 4602505 [No Abstract] [Full Text] [Related]
45. Low-dose methotrexate therapy and hepatotoxicity. The view of the hepatologist. Watson RG; Smallwood RA Med J Aust; 1991 Oct; 155(7):428-30. PubMed ID: 1921807 [No Abstract] [Full Text] [Related]
50. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Kaur I; Dogra S; De D; Kanwar AJ Pediatr Dermatol; 2008; 25(2):184-8. PubMed ID: 18429775 [TBL] [Abstract][Full Text] [Related]
53. Methotrexate and etretinate as concurrent therapies in the treatment of psoriasis. Zachariae H Arch Dermatol; 1984 Feb; 120(2):155. PubMed ID: 6696467 [No Abstract] [Full Text] [Related]
54. Liver damage and methotrexate. Baker H Br Med J; 1971 Jun; 2(5764):776. PubMed ID: 5090795 [No Abstract] [Full Text] [Related]
59. Short-term observations in the use of intravenous methotrexate in the treatment of psoriasis. Land WA Australas J Dermatol; 1967 Dec; 9(2):183-8. PubMed ID: 5588857 [No Abstract] [Full Text] [Related]
60. [Limitations and risks of therapy of psoriasis with amethopterin and hydroxyurea]. Ottolenghi F; Andreassi L G Ital Dermatol Minerva Dermatol; 1971 Sep; 46(9):385-96. PubMed ID: 4255617 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]